TL;DR: Aetna, a CVS Health company, modified CPB 0606 governing autologous hematopoietic cell transplantation for autoimmune diseases, effective September 26, 2025. Here's what billing teams need to do.
This update to the Aetna hematopoietic cell transplantation coverage policy tightens the medical necessity criteria for adults with rapidly progressive scleroderma. The change directly affects CPT codes 38206 and 38241 — the autologous harvesting and transplantation codes — along with the broader code set under CPB 0606 in the Aetna system. If your practice or facility bills stem cell transplants for autoimmune indications, this update changes what you need to document before submitting a claim.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Hematopoietic Cell Transplantation for Autoimmune Diseases and Miscellaneous Indications |
| Policy Code | CPB 0606 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | High |
| Specialties Affected | Hematology/Oncology, Rheumatology, Pulmonology, Transplant Centers |
| Key Action | Audit documentation for FVC, DLCO, creatinine clearance, and LVEF values before submitting CPT 38241 for scleroderma patients |
Aetna Hematopoietic Cell Transplantation Coverage Criteria and Medical Necessity Requirements 2025
CPB 0606 in the Aetna system now specifies exactly what clinical thresholds a patient must meet before autologous hematopoietic cell transplantation (HCT) qualifies as medically necessary for scleroderma. This is not a blanket approval for systemic sclerosis. The patient must meet specific pulmonary or renal criteria — and must clear a separate set of exclusion criteria — before the coverage policy applies.
Here's the core medical necessity gate. The patient must be an adult aged 18 to 69 with rapidly progressive scleroderma at risk of organ failure. Then they must meet one of two entry criteria:
| # | Covered Indication |
|---|---|
| 1 | Active interstitial lung disease confirmed by broncho-alveolar cell composition or ground-glass opacities on chest CT, plus either an FVC or DLCO below 70% of predicted value; or |
| 2 | Previous scleroderma-related renal disease |
Meeting one of those two gets the patient into the coverage window. But they also need to clear the exclusion criteria — either by meeting the transplanting institution's selection criteria, or by having none of the following:
| # | Covered Indication |
|---|---|
| 1 | Creatinine clearance below 40 ml/min |
| 2 | DLCO below 40% of predicted value, or FVC below 45% of predicted value |
| 3 | Pulmonary arterial hypertension |
| 4 | Left ventricular ejection fraction (LVEF) below 50% |
The real issue here is the dual-gate structure. A patient can qualify on the lung disease criterion, then get disqualified because their DLCO has deteriorated further below 40%. Your clinical team and transplant coordinators need to check both gates — entry and exclusion — before submitting for prior authorization.
For billing, prior authorization is almost certainly required for CPT 38241 (autologous transplantation) and CPT 38206 (autologous blood-derived HPC harvesting) under this policy. Aetna's coverage policy for transplant procedures routinely requires prior auth. Confirm this with your Aetna provider agreement before the transplant workup begins — not after.
Reimbursement for the full transplant episode depends on clean documentation at each step. That means radiology reports confirming ground-glass opacities, pulmonary function tests with FVC and DLCO values expressed as percent of predicted, creatinine clearance labs, and an echocardiogram showing LVEF of 50% or higher. Missing any one of these is a direct path to claim denial.
Aetna Hematopoietic Cell Transplantation Exclusions and Non-Covered Indications
The HCPCS codes S2140, S2142, and S2150 are explicitly not covered for the indications listed in CPB 0606. These cover cord blood harvesting (S2140), cord blood-derived stem-cell transplantation (S2142), and general bone marrow or blood-derived stem cell harvest/transplant services (S2150).
If your facility bills cord blood transplant services under any of the autoimmune indications covered by CPB 0606, expect denial. These procedures fall outside Aetna's coverage policy for this indication set regardless of clinical rationale. The policy draws a hard line between autologous transplantation using the patient's own cells and cord blood or allogeneic approaches.
Do not attempt to substitute these HCPCS codes for the covered CPT codes. They are structurally different procedures, and Aetna has broken them out separately for a reason.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Rapidly progressive scleroderma (systemic sclerosis) with active interstitial lung disease + FVC or DLCO <70% | Covered (when exclusion criteria not met) | CPT 38206, 38241; ICD-10 varies | Must confirm ground-glass opacities or BAL findings on chest CT; prior auth required |
| Rapidly progressive scleroderma with prior scleroderma-related renal disease | Covered (when exclusion criteria not met) | CPT 38206, 38241 | Renal disease must be scleroderma-related; document clinical history clearly |
| Any indication with creatinine clearance <40 ml/min | Not covered / excluded | — | Absolute exclusion; no exceptions noted |
| Any indication with DLCO <40% predicted or FVC <45% predicted | Not covered / excluded | — | Severe lung disease exclusion; overlaps with entry criteria — confirm values carefully |
| Any indication with pulmonary arterial hypertension | Not covered / excluded | — | Absolute exclusion regardless of other criteria |
| Any indication with LVEF <50% | Not covered / excluded | — | Poor cardiac function exclusion; echocardiogram required |
| Cord blood harvesting or transplantation for listed indications | Not covered | HCPCS S2140, S2142, S2150 | Explicitly excluded under CPB 0606 |
Aetna Hematopoietic Cell Transplantation Billing Guidelines and Action Items 2025
The effective date of September 26, 2025 is already in effect. If you're scheduling transplants now for patients with scleroderma, these criteria apply today.
| # | Action Item |
|---|---|
| 1 | Audit your pre-authorization packets for all pending scleroderma HCT cases. Confirm that each packet includes chest CT reports with ground-glass opacity findings or BAL results, PFTs with FVC and DLCO as percent of predicted, creatinine clearance, and an echocardiogram with LVEF. Any packet missing these values will fail the medical necessity review. |
| 2 | Flag the dual-gate structure in your prior auth workflow. Build a checklist that separates the entry criteria from the exclusion criteria. A patient can pass the first gate and fail the second. Your prior auth team needs to check both before submitting. |
| 3 | Remove HCPCS codes S2140, S2142, and S2150 from any charge capture templates tied to autoimmune HCT indications. These are not covered under CPB 0606. Using them will generate a claim denial that's hard to appeal given the explicit policy language. |
| 4 | Update your hematopoietic cell transplantation billing templates to default to CPT 38206 for autologous harvesting and CPT 38241 for autologous transplantation when billing scleroderma cases. Use CPT 38204 for donor search and cell acquisition management when applicable. |
| 5 | Confirm the age cutoff with your scheduling team. Coverage applies to adults aged 18 to 69. A 70-year-old patient does not meet the policy criteria. Catch this before the prior auth is submitted, not after. |
| 6 | Pull ICD-10 coding from your rheumatology documentation carefully. Scleroderma-related codes need to align with the CPB 0606 indication. If your rheumatologist is documenting a mixed connective tissue disease or an overlap syndrome, the coding may not map cleanly to the covered indication. Loop in your coder and your compliance officer if the diagnosis is ambiguous. |
| 7 | Talk to your compliance officer if your transplant volume for autoimmune indications is significant. The criteria here are narrow. If you're billing these codes at volume, a chart audit before the next submission cycle makes sense. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Hematopoietic Cell Transplantation Under CPB 0606
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 38204 | CPT | Management of recipient hematopoietic progenitor cell donor search and cell acquisition |
| 38205 | CPT | Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic |
| 38206 | CPT | Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous |
| 38207 | CPT | Bone marrow or stem cell services/procedures |
| 38208 | CPT | Bone marrow or stem cell services/procedures |
| 38209 | CPT | Bone marrow or stem cell services/procedures |
| 38210 | CPT | Bone marrow or stem cell services/procedures |
| 38211 | CPT | Bone marrow or stem cell services/procedures |
| 38212 | CPT | Bone marrow or stem cell services/procedures |
| 38213 | CPT | Bone marrow or stem cell services/procedures |
| 38214 | CPT | Bone marrow or stem cell services/procedures |
| 38215 | CPT | Bone marrow or stem cell services/procedures |
| 38230 | CPT | Bone marrow harvesting for transplantation; allogeneic or autologous |
| 38231 | CPT | Bone marrow harvesting for transplantation; allogeneic or autologous |
| 38232 | CPT | Bone marrow harvesting for transplantation; allogeneic or autologous |
| 38240 | CPT | Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor |
| 38241 | CPT | Autologous transplantation |
| 86813 | CPT | HLA typing; A, B or C, multiple antigens |
| 86817 | CPT | DR/DQ, multiple antigens |
| 86821 | CPT | Lymphocyte culture, mixed (MLC) |
| 86920 | CPT | Compatibility test each unit |
| 86921 | CPT | Compatibility test each unit |
| 86922 | CPT | Compatibility test each unit |
| 86923 | CPT | Compatibility test each unit |
Not Covered HCPCS Codes
| Code | Type | Description | Reason |
|---|---|---|---|
| S2140 | HCPCS | Cord blood harvesting for transplantation, allogeneic | Not covered for indications listed in CPB 0606 |
| S2142 | HCPCS | Cord blood-derived stem-cell transplantation, allogeneic | Not covered for indications listed in CPB 0606 |
| S2150 | HCPCS | Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvest and transplantation | Not covered for indications listed in CPB 0606 |
Key ICD-10-CM Diagnosis Codes
The full ICD-10-CM list under CPB 0606 runs to 221 codes. Below are the codes explicitly present in the policy data. Your billing team should cross-reference the full policy at the source before coding edge cases.
| Code | Description |
|---|---|
| D45 | Polycythemia vera |
| D46.9 | Myelodysplastic syndrome, unspecified (Behcet's disease with myelodysplastic syndrome) |
| D47.3 | Essential (hemorrhagic) thrombocythemia |
| D59.0 – D59.9 | Autoimmune hemolytic anemia (multiple specificity codes) |
| D68.61 | Antiphospholipid syndrome |
| D69.3 | Immune thrombocytopenic purpura |
| D69.41 | Evans syndrome |
| D71 | Functional disorders of polymorphonuclear neutrophils (chronic granulomatous disease) |
| E08.00 – E13.9 | Diabetes mellitus |
| E75.4 | Neuronal ceroid lipofuscinosis |
| F84.0 – F84.9 | Pervasive developmental disorders |
| G12.21 | Amyotrophic lateral sclerosis |
| G25.82 | Stiff-man syndrome |
| G35 | Multiple sclerosis |
| G36.0 | Neuromyelitis optica (Devic) |
| G61.81 | Chronic inflammatory demyelinating polyneuritis |
| G70.0 – G70.1 | Myasthenia gravis |
| G72.49 | Other inflammatory and immune myopathies, not elsewhere classified |
| G90.3 | Multi-system degeneration of the autonomic nervous system |
| H16.321 – H16.325 | Diffuse interstitial keratitis |
The full ICD-10-CM list includes 221 codes spanning autoimmune, neurological, metabolic, hematologic, and developmental conditions. Pull the complete list from the Aetna CPB 0606 source document before mapping diagnosis codes to claims. Coding to an ICD-10 that doesn't appear on the covered list is a fast path to claim denial with limited appeal options.
Get the Full Picture for CPT 38241
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.